Pralidoxime

From Wikipedia, the free encyclopedia
  (Redirected from 2-PAM)
Jump to: navigation, search
Pralidoxime
Pralidoxime-2D-skeletal.png
Pralidoxime-3D-vdW.png
Clinical data
AHFS/Drugs.com Micromedex Detailed Consumer Information
Pregnancy
category
  • C
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
Synonyms 1-methylpyridine-6-carbaldehyde oxime
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
ECHA InfoCard 100.027.080
Chemical and physical data
Formula C7H9N2O+
Molar mass 137.159 g/mol
3D model (Jmol)
  (verify)

Pralidoxime (2-pyridine aldoxime methyl chloride) or 2-PAM, usually as the chloride or iodide salts, belongs to a family of compounds called oximes that bind to organophosphate-inactivated acetylcholinesterase.[1] It is used to combat poisoning by organophosphates[2] or acetylcholinesterase inhibitors (nerve agents) in conjunction with atropine and diazepam. It is a white solid.

Chemical synthesis[edit]

Pralidoxime, 2-pyridinaldoxime methylchloride, is prepared by treating pyridine-2-carboxaldehyde with hydroxylamine. The resulting pyridine-2-aldoxime is alkylated with methyl iodide giving pralidoxime as the iodide salt.[3][4][5][6]

Pralidoxime synthesis.png

Mechanism of action[edit]

Pralidoxime is typically used in cases of organophosphate poisoning. Organophosphates such as sarin bind to the hydroxy component (the esteric site) of the active site of the acetylcholinesterase enzyme, thereby blocking its activity. Pralidoxime binds to the other half (the unblocked, anionic site) of the active site and then displaces the phosphate from the serine residue. The conjoined poison / antidote then unbinds from the site, and thus regenerates the fully functional enzyme.

Some phosphate-acetylcholinesterase conjugate continue to react after the phosphate docks to the esteric site, evolving into a more recalcitrant state. This process is known as aging. Aged phosphate-acetylcholinesterase conjugate are resistant to antidotes such as pralidoxime. Pralidoxime is often used with atropine (a muscarinic antagonist) to help reduce the parasympathetic effects of organophosphate poisoning. Pralidoxime is only effective in organophosphate toxicity. It has no beneficial effects if the acetylcholinesterase enzyme is carbamylated, as occurs with neostigmine, pyridostigmine, or insecticides such as carbaryl.

Pralidoxime has an important role in reversing paralysis of the respiratory muscles but due to its poor blood–brain barrier penetration, it has little effect on centrally-mediated respiratory depression. Atropine, which is choice of drug to antagonise the muscarinic effects of organophosphates, is administered even before pralidoxime during the treatment of organophosphate poisoning. While the efficacy of atropine has been well-established, clinical experience with pralidoxime has led to widespread doubt about its efficacy in treatment of organophosphorus poisoning.[7]

Dosage[edit]

Intravenous infusions can lead to respiratory or cardiac arrest if given too quickly.[8]

Interactions[edit]

When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. This is especially true if the total dose of atropine has been large and the administration of pralidoxime has been delayed.

The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions; morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.

Contraindications[edit]

There are no known absolute contraindications for the use of pralidoxime. Relative contraindications include known hypersensitivity to the drug and other situations in which the risk of its use clearly outweighs possible benefit.

See also[edit]

References[edit]

  1. ^ Jokanović M.; Stojiljković, M. P. (2006). "Current understanding of the application of pyridinium oximes as cholinesterase reactivators in treatment of organophosphate poisoning". Eur J Pharmacol. 553: 10–7. doi:10.1016/j.ejphar.2006.09.054. 
  2. ^ Jokanović M, Prostran M (2009). "Pyridinium oximes as cholinesterase reactivators. Structure-activity relationship and efficacy in the treatment of poisoning with organophosphorus compounds". Curr. Med. Chem. 16 (17): 2177–88. doi:10.2174/092986709788612729. PMID 19519385. 
  3. ^ D. Nachmansonn, S. Ginsburg, U.S. Patent 2,816,113 (1957)
  4. ^ L. P. Black, U.S. Patent 3,123,613 (1964)
  5. ^ D.E. Easterday, A.A. Kondritzer, U.S. Patent 3,140,289 (1964)
  6. ^ W.B. McDowell, U.S. Patent 3,155,674 (1964)
  7. ^ [2]Banerjee I, Tripathi S K, Roy A S. Efficacy of pralidoxime in organophosphorus poisoning: Revisiting the controversy in Indian setting. J Postgrad Med 2014;60:27-30
  8. ^ Baxter Healthcare Corporation 2006, Protopam Prescribing Information

External links[edit]